Brean Murray Carret & Co.
http://www.breanmurraycarret.com/
Brean Murray & Co., Inc. was founded in 1973 as a research-driven investment and merchant bank, focusing on growth companies to provide clients with superior investment opportunities.
Brean Murray's services include equity research, investment banking, institutional sales and trading, syndicate, and asset management. The Company's clients include institutional investors, high net worth individuals and corporations that use its capital markets services to take advantage of compelling market opportunities.
Brean Murray, Carret & Co. has also established a presence in Beijing, bringing over three decades of investment banking and brokerage experience to mainland China.
View Older Stories
-
Brean Murray Positive on Vivus (VVUS) after Approval
-
Brean Murray Says Vivus (VVUS) Qnexa Delay 'Makes Perfect Sense' and is a Positive
-
Brean Murray Adds Achillion (ACHN), Pitney Bowes (PBI), Vivus (VVUS) to 'Focus List'; Removes Gilead (GILD)
-
FDA Says Existing Applications for Obesity Drugs Unlikely to Be Affected by Panel Findings (VVUS) (ARNA) (OREX)
-
Brean Murray Carret & Co. Upgrades Vivus (VVUS) to Buy After FDA's Cardiovascular Advisory Panel Meeting
-
Streetinsider.com's Hot Lunchtime Reads 03/06: (VVUS) (THQI) (AAPL) (FSLR) (EXPR)
-
Brean Murray Carret & Co. Upgrades Vivus (VVUS) to Hold; Removed From N-T Conviction List as Large Panel Vote Surprises
-
Streetinsider.com's Hot Lunchtime Reads 02/22: (CCL) (SIMO) (RSH) (WPRT) (TIVO)
-
Brean Murray Carret & Co. Maintains a 'Sell' on Vivus; Orexigen (OREX) News Not Immediately Relevant to VVUS
-
Brean Murray Carret & Co. Reiterates Sell Rating and $2 Price Target on Vivus (VVUS), No Real Signs Of Success
-
Game Over For VIVUS (VVUS) According to Brean Murray
-
Notable Analyst Rating Changes 08/03: NWL, MTW, SHPGY, PHH Upgraded; AMAT, SYKE, AZO, VVUS Downgraded
-
Brean Murray Cuts VIVUS (VVUS) to Sell Amid Q2 Miss; $2 Price Target Implies 64% Slide in Stock Price
-
Unusual 11 Mid-Day Movers 07/16: LSBX, ARNA, AVII, CYPB, SCHW, TSLA Higher; VVUS, JST, ROIAK, OREX, PLCM Lower
-
Notable Analyst Rating Changes 07/16: GS, JPM, ARNA, ADM Upgraded; VVUS, BP, RBA, OREX Downgraded
-
Morning Movers 7/16: LSBX, ARNA, AVII Higher; VVUS, JST, VRNM, BIOF, VIDE, PLCM Lower
-
Brean Murray Downgrades VIVUS (VVUS) to Hold
-
Brean Murray Sees VIVUS's (VVUS) Qnexa Gaining FDA Approval, Raises Target to $18
-
Vivus (VVUS) option prices elevated into data
-
Notable Analyst Rating Changes 04/27: PPDI, MRVL, TASR, CAVM Upgraded; AIG, HBAN, NWSA, ACN Downgraded
-
Brean Murray Initiates Coverage on VIVUS, Inc. (VVUS) with a Buy; Meaningful Near-Term Catalysts

